SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

"What's Updog?" is a Community Led token.

UpDog

UpDog is generating significant buzz as community members highlight its long-standing presence on the Solana network and its inclusion on the Jupiter strict list. Investors are actively discussing the token's organic growth and recent price action, with many focusing on whale accumulation and shared dad-joke-themed community sentiment.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently experiencing heightened community debate as investors weigh the project's long-term utility and ecosystem expansion against ongoing price stagnation and concerns over lack of executive communication. The discourse is polarized between long-term holders actively accumulating positions in anticipation of future news and skeptical observers who remain critical of the project's recent performance compared to the broader crypto market.

Shiba Inu (SHIB) is a decentralized, community-led cryptocurrency ecosystem built on the Ethereum blockchain. Originally launched as a meme-based project, it has evolved into a comprehensive financial ecosystem designed to offer a decentralized alternative to traditional banking. Its main value proposition lies in its transition from a social phenomenon into a functional utility network, supported by a vast global community known as the ShibArmy and a commitment to 100% community ownership with no central leadership.  The ecosystem features its own decentralized exchange, ShibaSwap, where users can trade, provide liquidity, and earn rewards. To address Ethereum’s high costs and slow speeds, the project utilizes Shibarium, a Layer 2 scaling solution that processes transactions faster and more affordably.  The project employs a unique three-token model to manage its economy and governance. SHIB serves as the primary currency for trading and payments, while LEASH offers scarcity-based incentives for dedicated supporters. BONE acts as the governance token, allowing holders to vote on proposals through the Doggy DAO and serving as the native gas token for the Shibarium network.

Shiba Inu

Shiba Inu is currently a focal point for investors debating its long-term viability, with community members polarized between those optimistic about ecosystem utility and potential breakouts and critics labeling it a fraudulent project. Discussions are heavily driven by speculative price targets, burn rate expectations, and comparisons to emerging meme assets, while some participants remain focused on holding through periods of stagnation.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant interest as institutional stakeholders and whales increase their accumulation, leading to discussions about long-term upside potential and supply constraints. The community remains actively divided, with many traders closely monitoring critical price levels for signs of a sustained breakout while others debate the impact of regulatory developments and the broader market sentiment.

Jupiter is a cryptocurrency exchange platform on the Solana blockchain, offering features such as token swapping, limit orders, dollar-cost averaging, and a bridge for asset transfers to Solana. It provides users with tools to find the best trading prices and includes a beta version for perpetual futures trading. Jupiter finds the best price route for your swap by aggregating all the major liquidity sources on Solana.

Jupiter

Jupiter's ecosystem continues to generate strong community engagement, with active discussions focused on the long-term potential of projects like $UPDOG and the ongoing innovation within Solana's DEX and lending sectors.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is experiencing a surge in social media activity and trading volume as the community rallies around hopes of a potential recovery, fueled by ongoing token burn initiatives and anticipation of broader regulatory clarity. Investors are actively discussing the project's long-term potential and decentralized utility, with many holders remaining committed despite past volatility.

KAT is a defi token with governance-like mechanics for Katana.  It is designed to function as a lever for directing capital: users that lock KAT receive a voting version of KAT — vKAT — in return. vKAT underpins key aspects of the chain’s economy, providing rewards to those users that participate. these fee-based rewards function as an incentive for KAT holders to engage in cooperative, positive-sum behavior.

Katana

Katana (KAT) is trending as the community debates its potential for massive growth following the adoption of new veKAT tokenomics and increased exchange visibility. While bulls highlight the intuitive DeFi utility and staking opportunities as indicators of an undervalued asset, skeptics remain vocal, labeling the project a speculative pump-and-dump candidate.

Monero

Monero is experiencing significant community buzz as investors pivot toward privacy-focused assets amid concerns over surveillance and shifting regulatory landscapes. The conversation is centered on its perceived role as a true store of value and an anonymous alternative to mainstream crypto, with many users debating its potential for long-term appreciation relative to Bitcoin.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as investors rally around its anticipated presence and potential partnership announcements at the upcoming XRP Vegas conference. Community sentiment remains polarized, with vocal long-term holders emphasizing the project's utility and ISO 20022 compliance, while skeptics debate its volatility and long-term price potential.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell is experiencing increased market attention driven by ongoing speculation regarding a potential acquisition of BP and strategic efforts to strengthen its global leadership in the LNG market. Investors are closely monitoring these M&A rumors alongside the company's commitment to maintaining robust shareholder returns and share buyback programs.

statis crypto Watchlist

Bitcoin

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Average Rating of "Hold" from Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) has been given an average rating of "Hold" by the seven brokerages that are presently covering the company, Marketbeat reports. One...

Zentalis Pharmaceuticals, Inc. $ZNTL Shares Acquired by JPMorgan Chase & Co.

JPMorgan Chase & Co. increased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 31.4% during the third quarter, according to its most recent filing with the Securities...

Pharmaceutical Stocks To Follow Today - April 10th

Eli Lilly and Company, Abbott Laboratories, Pfizer, AbbVie, Novo Nordisk A/S, Organon & Co., and Zentalis Pharmaceuticals are the seven Pharmaceutical stocks to watch today, according to MarketBeat's...

What's Behind The Surge In Zentalis Stock?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) shares are surging Friday after a Guggenheim analyst raised the price target from $6 to $10.read more...

<ul class="summary-bullets"><li>Zentalis selected the 400 mg dose of its drug to treat ovarian cancer after it showed a higher response rate than the 300 mg dose.</li><li>The company expects to complete enrollment and report topline results from the trial by the end of 2026.</li><li>This comes just two weeks after the FDA approved Cort’s ovarian cancer treatment months ahead of schedule.</li></ul>Shares of Zentalis Pharmaceuticals (ZNTL) soared over 40% on Friday to their highest level since June 2024, after a bullish analyst call highlighted improved efficacy from a higher dose of its ovarian cancer drug while maintaining a comparable safety profile.Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating, according to The Fly. This implies a potential 56% upside from the stock’s current price. The firm cited the price target change to the increased confidence in the drug’s chances of success in platinum-resistant ovarian cancer.<h2 class="st-heading-2">Zentalis Picks 400 MG Dose For Future Trials</h2>On Thursday, Zentalis announced encouraging interim results from its DENALI Part 2a study of Azenosertib, an oral therapy, in platinum-resistant ovarian cancer, supporting the drug’s further late-stage development.The biotech firm selected the 400 mg once-daily dose (five days on, two days off) after it showed a clearly higher response rate than the 300 mg dose, while maintaining a similar safety profile. The 400 mg dose will now be used in the ongoing Phase 2 DENALI trial and the Phase 3 ASPENOVA study.Zentalis expects to complete enrollment and report topline results from the DENALI Part 2 trial by the end of 2026.<h2 class="st-heading-2">FDA Approved Corcept’s Ovarian Cancer Drug Months Ahead Of PDUFA Date</h2>The results are crucial, as they allow Zentalis to move towards potential regulatory approval. Just two weeks earlier, the U.S. Food and Drug Administration (FDA) <a href="https://stocktwits.com/news-articles/markets/equity/cort-stock-skyrockets-35-after-early-fda-nod-for-ovarian-cancer-drug/cZ3YMziRISr">approved</a> Corcept Therapeutics’ (CORT) ovarian cancer treatment.The approval covers adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received treatment.Notably, the FDA’s decision came way ahead of schedule, as the therapy had been assigned a Prescription Drug User Fee Act (PDUFA) target date of July 11, 2026.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ZNTL">ZNTL</a> on Stocktwits changed to ‘extremely bullish’ from ‘bullish,’ amid ‘extremely high’ message volumes.One user expects the company’s valuation to explode seven to 10-fold if the drug is successful in monotherapy.<stembedurl>https://stocktwits.com/Lukey63/message/649876699</stembedurl>However, another user said the stock is overvalued, highlighting the company’s pipeline.<stembedurl>https://stocktwits.com/ScorpionScarlet/message/649934768</stembedurl>Year-to-date, the stock has shot up more than 370%.&nbsp;

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

This Small-Cap Biotech Stock Just Hit A Near 22-Month High – But This Analyst Still Expects Another 56% Rally

Guggenheim raised Zentalis’ price target to $10 from $6 and maintained a ‘Buy’ rating after the company posted the interim results for its ovarian cancer drug.

ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update

Equity

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Price Target Raised to $10.00

Guggenheim lifted their target price on shares of Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a "buy" rating in a research note on Friday...

These Stocks are Heating Up Fast

Top stocks to trade this afternoon. $ONCO, $KBLB, $ARAI, $EOSE, $ZNTL

Brokers Issue Forecasts for ZNTL FY2030 Earnings

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities research analysts at HC Wainwright issued their FY2030 earnings estimates for Zentalis Pharmaceuticals in a report released on...

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen cut Zentalis Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday...

Zentalis Pharmaceuticals' (ZNTL) "Buy" Rating Reiterated at Guggenheim

Guggenheim reaffirmed a "buy" rating and issued a $6.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday...

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.48	--	--	N/A
Q4 '25	-$0.47	-$0.50	-7.34%	MISSED
Q3 '25	-$0.53	-$0.37	29.90%	BEAT
Q2 '25	-$0.59	-$0.37	37.67%	BEAT
Q1 '25	-$0.64	-$0.67	-5.08%	MISSED

ZNTL
Zentalis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest ZNTL News

ZNTLZentalis Pharmaceuticals Inc